Potential to Double Cancer Cure: Princess Margaret 2014 Conference
On Feb. 10-11, 2014, the Princess Margaret Cancer Centre - the largest comprehensive cancer centre in Canada and one of the world #39;s top five - hosted its inaugural conference, "Beyond the Genetic...

By: Princess Margaret Cancer Centre

Read this article:
Potential to Double Cancer Cure: Princess Margaret 2014 Conference - Video

Recommendation and review posted by sam

8th Annual Chair-Leader Event - Part 1
On May 7th, 2014 Members of Parliament representing all political parties cam together to participate in the 8th annual Chair-Leaders Campaign to raise awareness regarding accessibility barriers....

By: Spinal Cord Injury Canada TV

See the original post:
8th Annual Chair-Leader Event - Part 1 - Video

Recommendation and review posted by sam

Spinal cord injury patient in harness walking

By: Chelsey Hensgen

More:
Spinal cord injury patient in harness walking - Video

Recommendation and review posted by sam

Spinal Cord Injury Before Stem Cell Transplantation
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

Read more from the original source:
Spinal Cord Injury Before Stem Cell Transplantation - Video

Recommendation and review posted by sam

Multiple Sclerosis Treatment through Stem Cells
Michael Racke, MD shares the latest advancements in stem cell research to providing treatment for Multiple Sclerosis at Ohio State University Wexner Medical Center.

By: osumedicalcenter

Read more:
Multiple Sclerosis Treatment through Stem Cells - Video

Recommendation and review posted by simmons

St. Petersburg, FL (PRWEB) May 20, 2014

A breakthrough for rejuvenating aging skin today includes topical stem cells rich in Growth Factors. These are non-embryonic stem cells.

Collagen is lost during the aging process as production slows down, a contributing factor in the formation of wrinkles, lines, sagging and thinning of skin.

"A very effective way to reduce wrinkles, improve skin quality and boost collagen levels is through Human Fibroblast Conditioned Media," says Kathy Heshelow, founder of Sublime Beauty. "Human Fibroblast Conditioned Media contains key ingredients for rejuvenation of skinespecially natural Growth Factors and other proteins."

2 reasons why these Growth Factors are key for anti-aging skin care:

1) Growth Factors, when used topically, stimulate skin to create more collagen. Results include smoother, healthier skin with diminished wrinkles. Collagen is the structure holding up skin, essential for smoothness.

2) Growth Factors help to replace and regenerate the nutrients needed by skin for rejuvenation. It promotes skin tissue repair and strengthens the elastic fibers which give the skin its softness and suppleness.

"We added our stem cell serum to the Sublime Beauty line for those that wanted a higher end, scientific formula," says Heshelow. "Our serum is of high purity with no fillers and is made in the U.S under strict conditions."

Expensive to make, Heshelow says the Sublime Beauty serum is less expensive than many similar serums found on the market, which can range from $300 to $500. "Our serum retails under $160," Heshelow says.

Use twice daily and see first results in about 2 weeks.

Follow this link:
2 Reasons Why Growth Factors and Stem Cells are a Breakthough for Aging Skin, Says Sublime Beauty

Recommendation and review posted by Bethany Smith

This post is sponsored by DIA.

Regenerative medicines and the latest regulatory issues surrounding them will be a hot topic for discussion at the DIA 2014 50th Annual Meeting. This years Annual Meeting will be in San Diego from June 15 to 19 and will feature a session titled Pioneering Regenerative Medicine: Trends in Regulations for New Therapy, under the Nonclinical and Translational Development/Early Phase Clinical Development track.

The session, to be held on June 16 from 8:30-10:00 AM, will introduce the first clinical research of induced pluripotent stem (iPS) cell products in Japan and review the current regulatory status and governmental efforts surrounding regenerative medicine. Speakers will also identify issues in the application of the new technology and discuss possible solutions.

iPS cells hold great promise in the field of regenerative medicine because they can propagate indefinitely, as well as give rise to every other cell type in the body such as neurons, heart, pancreatic, and liver cells, and therefore represent a single source of cells that could be used to replace those lost to damage or disease. iPS cell technology was pioneered by Shinya Yamanaka of Kyoto, Japan, who was awarded the 2012 Nobel Peace Prize for the discovery alongside Sir John Gurdon.

The session will be chaired by Shinji Miyake, PhD, Professor of the Center for Clinical Research at Keio University School of Medicine in Japan.

The DIA 2014 50th Annual Meeting: Celebrate the Past Invent the Future is the largest multidisciplinary event that brings together a community of life sciences professionals at all levels and across all disciplines involved in the discovery, development, and life cycle management of medical products all with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies to patients.

This years event celebrates DIAs 50th Anniversary and will feature 260+ educational offerings over 21 tracks, 450+ exhibiting companies, over 125 representatives from global regulatory agencies, and much more. The meeting provides participants with a valuable opportunity to network with professionals from around the world, share knowledge, and build new relationships.

Find out more about DIA 2014 50th Annual Meeting at http://www.diahome.org/DIA2014.

Get our daily newsletter or follow us.

Please enter your email below:

Excerpt from:
Introducing pioneering regenerative medicine

Recommendation and review posted by Bethany Smith

Freeport, The Bahamas (PRWEB) May 20, 2014

Okyanos Heart Institute has announced the addition of Dr. Todd Malan to their executive medical team as Chief Cell Therapy Officer and General Surgeon. He will perform and oversee the liposuction step of Okyanos treatment, removing a small amount of fat from patients from which their own stem cells are isolated. Cardiac cell therapy is intended for no-option heart patients who have exhausted the currently available standards of care for their condition, of which there are about 2 million in the United States alone.

Dr. Malan is founder of the Innovative Cosmetic Surgery Center in Scottsdale, Arizona, specializing in advanced liposuction and fat transfer procedures. A pioneer in adipose- (fat) derived stem cell research and fellow of the American Academy of Cosmetic Surgery, Dr. Malan became the first physician in the United States to utilize adult stem cells from fat tissue for soft tissue reconstruction. He has co-authored two medical textbooks on fat-derived stem cell therapies and has served as principal investigator on two Institutional Review Board- (IRB) approved adult stem cell trials.

As an active member of the adipose stem cell research community, Dr. Malan is very familiar with the therapeutic benefits of adult stem cells for cardiac, as demonstrated in clinical trials, said Dr. Howard Walpole, chief medical officer at Okyanos. He lends his experience and integrated knowledge of both innovative cosmetic surgery and stem cell therapy to our medical leadership team, he added.

"It is truly gratifying to see the gathering of like-minded researchers, clinicians, and administrators who see the remarkable value of developing evidence-based protocols for effective stem cell therapies, said Dr. Malan. He added, This project is a culmination of years of experience between industry leaders who are dedicated to making Okyanos a premier cell therapy center in the world. The work we do today will define the future of medicine for years to come."

Okyanos cardiac cell therapy is the first stem cell-based procedure for heart failure available to patients outside of clinical trials, wherein the patients own adipose-derived stem cells are infused directly into the damaged part of the heart via catheter. Okyanos will begin treating advanced heart disease patients in Freeport, The Bahamas, in the summer of 2014.

ABOUT OKYANOS HEART INSTITUTE: [Oh key AH nos] Based in Freeport, The Bahamas, Okyanos Heart Institutes mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by founder and CEO Matt Feshbach, as well as Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.S.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from ones own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive procedure, can stimulate the growth of new blood vessels, a process known as angiogenesis. Angiogenesis facilitates blood flow in the heart, which supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos, the Greek god of rivers, symbolizes restoration of blood flow.

For more information, please visit http://www.okyanos.com/.

Read more:
Dr. Todd Malan Named Chief Cell Therapy Officer at Okyanos Heart Institute

Recommendation and review posted by Bethany Smith

DNA, cloning, and genetic engineering
via YouTube Capture.

By: Lindsey Jackson

See the rest here:
DNA, cloning, and genetic engineering - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

20-May-2014

Contact: Kathryn Ruehle kruehle@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 20, 2014Studies have identified mobile phones and related devices as sources of metal sensitization and potential causes of allergic contact dermatitis (ACD). Despite efforts to control allergen release in phones, many phones on the market release levels of metals, such as nickel and chromium, which are sufficient to induce ACD, according to an article in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc., publishers. The article is available free on the Pediatric Allergy, Immunology, and Pulmonology website at http://online.liebertpub.com/doi/full/10.1089/ped.2013.0308.

In the article "Mobile Phone Dermatitis in Children and Adults: A Review of the Literature," a team of researchers led by Jacob Thyssen, MD, PhD, Copenhagen University Hospital Gentofte (Hellerup, Denmark), Loma Linda University School of Medicine (Loma Linda, CA), and University of Arizona College of Medicine (Phoenix, AZ), review the current literature on mobile phone dermatitis in both children and adults. Nickel sensitization is common in children, resulting in ACD prevalence levels of up to 33%. This information is important for practitioners, particularly when evaluating patients with dermatitis of the face, neck, hands, breast, or anterior thighscommon places exposed to cell phones. The authors provide important diagnostic tips for practitioners and strategies to raise awareness of nickel- or chromium-induced mobile phone ACD.

"With the rising use of cell phones and other mobile devices, pediatricians can expect to see additional cases of ACD," says Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, State University of New York at Stony Brook (Stony Brook, NY) and practicing pediatric pulmonologist at Winthrop University Hospital. "Thyssen's paper discusses diagnostic patch testing for common metal allergens and the value of spot testing of the patient's phone in establishing a causal relationship."

###

About the Journal

Pediatric Allergy, Immunology, and Pulmonology is a quarterly peer-reviewed journal published in online with Open Access options and in print. The Journal synthesizes the pulmonary, allergy, and immunology communities in the advancement of the respiratory health of children. The Journal provides comprehensive coverage to further the understanding, and optimize the treatment, of some of the most common and costly chronic illnesses in children. It includes original translational, clinical, and epidemiologic research; public health, quality improvement, and case control studies; patient education research; and the latest research and standards of care for functional and genetic immune deficiencies and interstitial lung diseases. Tables of content and a sample issue may be viewed on the Pediatric Allergy, Immunology, and Pulmonology website at http://www.liebertpub.com/ped.

About the Publisher

More here:
Can mobile phones cause allergic reactions?

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

20-May-2014

Contact: Fiona Godwin medicinepress@plos.org PLOS

Targeted interventions based on genetic risk may not be the best approach for preventing type 2 diabetes and instead universal strategies to prevent obesity should be prioritized, according to new research published in this week's PLOS Medicine. This analysis, led by Claudia Langenberg from the MRC Epidemiology Unit at the University of Cambridge, UK, suggests that the contribution of genetics to the risk of developing type 2 diabetes is greatest in those who are younger and leaner. However, in this group, the absolute risk of developing type 2 diabetes is low and the number of people who would have to be screened in order to guide targeted prevention would be impractically large.

Diabetes is currently estimated to affect more than 380 million people and the epidemic is likely to increase to 592 million by 2035. Type 2 diabetes is thought to be caused by a combination of genetic and lifestyle factors, such as overweight and physically inactivity. While progress has been made in understanding the genetic basis of type 2 diabetes, the details of how adverse lifestyles combine with genetic risk to determine risk of developing type 2 diabetes are uncertain.

The authors quantified the association of genetic and lifestyle factors with the risk of developing type 2 diabetes in a large cohort of 340,234 people in 8 European countries followed for 11.7 years. In this EPIC-InterAct study, 12,403 people developed type 2 diabetes. The researchers identified an individual's genetic risk by determining how many of a list of 49 known type 2 diabetes genetic variants each study participant carried. They then assessed how this genetic risk contributed to each individual's overall risk of developing type 2 diabetes after several risk factors (such as age, waist circumference, physical activity and Mediterranean diet) were taken into account.

They found that the relative increase in risk of type 2 diabetes for each additional adverse gene carried was greatest in participants who were younger and thinner at baseline. However, risk of developing type 2 diabetes was highest in people who were obese, whatever their level of genetic risk for diabetes. The 10-year cumulative incidence of type 2 diabetes was substantially greater for those with the lowest genetic risk who were overweight (1.29%) or obese (4.22%) compared to normal weight individuals with the highest genetic risk (0.89%).

Professor Nick Wareham, who led the EPIC-InterAct study said "this is the largest study to date examining the impact of genetic susceptibility and lifestyle factors on the risk of developing type 2 diabetes". He added that, "the high absolute risk associated with obesity at any level of genetic risk highlights the importance of population-wide, rather than genetically targeted, approaches to promoting healthy lifestyles that minimise excess weight".

###

Funding: No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding for the InterAct project was provided by the EU FP6 programme (grant number LSHM_CT_2006_037197). In addition, InterAct investigators acknowledge funding from the following agencies: PWF: Swedish Research Council, Novo Nordisk, Swedish Diabetes Association, Swedish Heart-Lung Foundation; PD: Work was supported by the Wellcome Trust; LCG: Swedish Research Council; MJT: Health Research Fund (FIS) of the Spanish Ministry of Health; Murcia Regional Government (Nu 6236); LA: EJD: The Spanish Ministry of Health ISCII RETICC RD06/0020; RK: German Cancer Aid, German Ministry of Research (BMBF); TJK: Cancer Research UK; KTK: Medical Research Council UK, Cancer Research UK; APM: Wellcome Trust grant numbers WT098017 and WT090532; CN: Health Research Fund (FIS) of the Spanish Ministry of Health; Murcia Regional Government (Nu 6236); PMN: Swedish Research Council; KO: Danish Cancer Society; SP: Compagnia di San Paolo; JRQ: Asturias Regional Government; OR: The Vasterboten County Council; AMWS and DLvdA: Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands; RT: AIRE-ONLUS Ragusa, AVIS-Ragusa, Sicilian Regional Government; YTvdS: Verification of diabetes cases was additionally funded by NL Agency grant IGE05012 and an Incentive Grant from the Board of the UMC Utrecht; IB: Wellcome Trust grant 098051 and United Kingdom NIHR Cambridge Biomedical Research Centre; MIM: InterAct, Wellcome Trust (083270/Z/07/Z), MRC (G0601261); ER: Imperial College Biomedical Research Centre.

See more here:
Lifestyle interventions are better than genetic tests for preventing type 2 diabetes

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

20-May-2014

Contact: Melissa Morgenweck morgenwm@mskcc.org 646-227-3633 The JAMA Network Journals

Multiplexed testing of lung cancer tumors identified genetic alterations that were helpful in selecting targeted treatments. Patients that received matched therapy for lung cancer lived longer than patients who did not receive directed therapy, although randomized clinical trials are required to determine if this treatment strategy improves survival, according to a study in the May 21 issue of JAMA.

The introduction of targeted therapy has transformed the care of patients with lung cancers by incorporating tumor genotyping into treatment decisions. Adenocarcinoma, the most common type of lung cancer, is diagnosed in 130,000 patients in the United States and 1 million persons worldwide each year. Adenocarcinoma is also the type of lung cancer with a higher than 50 percent estimated frequency of actionable oncogenic drivers, which are molecular abnormalities that are critical to cancer development. These drivers are defined as "actionable" because the effects of those abnormalities can be negated by agents directed against each genomic alteration, according to background information in the article.

Mark G. Kris, M.D., of Memorial Sloan Kettering Cancer Center, New York, and colleagues examined the frequency of oncogenic drivers in patients with lung adenocarcinomas, and the proportion of patients in whom this data was used to select treatments targeting the identified driver(s) along with overall survival. From 2009 through 2012, 14 sites of the Lung Cancer Mutation Consortium enrolled patients with metastatic lung adenocarcinomas and tested the tumors of patients who met certain criteria for 10 oncogenic drivers.

During the study period, tumors from 1,007 patients were tested for at least 1 gene and 733 for 10 genes (patients with full genotyping). An oncogenic driver was found in 466 of 733 patients (64 percent). Results were used to select a targeted therapy or clinical trial in 275 of 1,007 patients (28 percent).

The 260 patients with an oncogenic driver and treatment with a targeted agent had a median (midpoint) survival of 3.5 years; the 318 patients with a driver and no targeted therapy, 2.4 years; and the 360 patients with no driver identified, 2.1 years.

The authors conclude that multiplexed tested aided physicians in selecting lung cancer therapies. Although individuals with drivers receiving a matched targeted agent lived longer, the study design was not appropriate to reach definitive conclusions about survival differences being attributable to the use of oncogenic drivers.

(doi:10.1001/jama.2014.3741; Available pre-embargo to the media at http://media.jamanetwork.com)

Read this article:
Research identifies genetic alterations in lung cancers that help select treatment

Recommendation and review posted by Bethany Smith

Attack of the B Team ep 16 Advanced Genetics
In this episode we make a hidden room and other cool stuff!!! DJ Snake Lil Jon - Turn Down for What.

By: Cody Thomas

See the original post:
Attack of the B Team ep 16 Advanced Genetics - Video

Recommendation and review posted by Bethany Smith

SWTOR Legacy Fanfiction: Locations, Genetics, Emperor #39;s Wrath, Hand of the Emperor
SWTOR Legacy Fanfiction: Genetics, Emperor #39;s Wrath and Hand Support the Creators, Don #39;t Block Ads! Play SWTOR for Free: http://play.any.tv/SHGn6 Shirts...

By: xLetalis

Continue reading here:
SWTOR Legacy Fanfiction: Locations, Genetics, Emperor's Wrath, Hand of the Emperor - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

20-May-2014

Contact: Raeka Aiyar, Ph.D. press@genetics-gsa.org 301-634-7302 Genetics Society of America

BETHESDA, MD (May 20, 2014) -- The Genetics Society of America (GSA) and the Drosophila research community are pleased to announce the winners of GSA Poster Awards at the 55th Annual Drosophila Research Conference, which took place in San Diego, March 26-30, 2014. These awards were made to undergraduate, graduate student, and postdoctoral researchers in recognition of the work they presented at the conference. Their projects, using the fruit fly Drosophila melanogaster as a model organism, spanned a diverse range of topics on the genetic and molecular basis of fundamental biological processes.

"We were very impressed with both the quality of the research and the clarity of presentation by the winning candidates," noted Adam P. Fagen, PhD, GSA's Executive Director. "It is gratifying to see such inspiring work by members of our community so early in their careers. We look forward to hearing much more about their contributions in the years to come. "

The recipients were chosen from 789 posters presented at the meeting, 561 of which were authored by GSA members and therefore eligible for an award.

2014 Drosophila Research Conference Poster Award Winners (for full release and photos, please visit the release URL http://www.genetics-gsa.org/media/releases/GSA_PR_20140520_Dros_poster_awards.pdf)

Postdoctoral Winners

FIRST PRIZE: Melanie I. Worley, University of California, Berkeley, USA Poster Title: "Chameleon: a mutant with an increased frequency of notum-to-wing transdetermination" Principal Investigator: Iswar K. Hariharan

SECOND PRIZE: Malini Natarajan, Stowers Institute for Medical Research, Kansas City, MO, USA Poster Title: "Genome-wide analysis of tissue-specific effector genes in the Drosophila embryo" Principal Investigator: Julia Zeitlinger

Read the original here:
Nine young scientists awarded by the Genetics Society of America for fruit fly research

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise BETHESDA, MD (May 20, 2014) -- The Genetics Society of America (GSA) and the Drosophila research community are pleased to announce the winners of GSA Poster Awards at the 55th Annual Drosophila Research Conference, which took place in San Diego, March 2630, 2014. These awards were made to undergraduate, graduate student, and postdoctoral researchers in recognition of the work they presented at the conference. Their projects, using the fruit fly Drosophila melanogaster as a model organism, spanned a diverse range of topics on the genetic and molecular basis of fundamental biological processes.

"We were very impressed with both the quality of the research and the clarity of presentation by the winning candidates," noted Adam P. Fagen, PhD, GSA's Executive Director. "It is gratifying to see such inspiring work by members of our community so early in their careers. We look forward to hearing much more about their contributions in the years to come."

The recipients were chosen from 789 posters presented at the meeting, 561 of which were authored by GSA members and therefore eligible for an award.

2014 Drosophila Research Conference Poster Award Winners (for the full release including photos, please see http://www.genetics-gsa.org/media/releases/GSA_PR_20140520_Dros_poster_awards.pdf)

Postdoctoral Winners

FIRST PRIZE: Melanie I. Worley, University of California, Berkeley, USA Poster Title: "Chameleon: a mutant with an increased frequency of notum-to-wing transdetermination" Principal Investigator: Iswar K. Hariharan

SECOND PRIZE: Malini Natarajan, Stowers Institute for Medical Research, Kansas City, MO, USA Poster Title: "Genome-wide analysis of tissue-specific effector genes in the Drosophila embryo" Principal Investigator: Julia Zeitlinger

THIRD PRIZE: Naoki Okamoto, RIKEN, Center for Developmental Biology (CDB), Kobe, Japan Poster Title: "Regulatory mechanism of the nutrient-dependent expression of Drosophila insulin-like peptide gene" Principal Investigator: Takashi Nishimura

Visit link:
Nine Young Scientists Awarded by the Genetics Society of America for Research Presented at Fruit Fly Conference

Recommendation and review posted by Bethany Smith

"In Your Genes" - Swedish Cancer Institute Personalized Medicine
http://SwedishCancerInstitute.org The Swedish Cancer Institute has a new weapon in the search for a cure. It #39;s personalized medicine, where DNA sequencing of a patient #39;s cancer cells helps...

By: swedishseattle

Continue reading here:
"In Your Genes" - Swedish Cancer Institute Personalized Medicine - Video

Recommendation and review posted by sam

19 May 2014

Hip surgery conducted with a 3D printed titanium implant and bone stem cell graft has been conducted in Southampton.

The 3D printed hip was designed using the patients CT scan and CAD CAM file, thereby matching the patients exact specifications and measurements.

According to Southampton University, the implant will provide a new socket for the ball of the femur bone to enter. Doctors have also inserted a graft containing bone stem cells behind the implant and between the pelvis .

The graft is said to acts as a filler for the loss of bone, with the patients own bone marrow cells added to the graft to provide a source of bone stem cells to encourage bone regeneration behind and around the implant.

The benefits to the patient through this pioneering procedure are numerous, said Douglas Dunlop, consultant orthopaedic surgeon who conducted the operation at Southampton General Hospital. The titanium used to make the hip is more durable and has been printed to match the patients exact measurements this should improve fit and could recue the risk of having to have another surgery. The bone graft material that has been used has excellent biocompatibility and strength and will fill the defect behind the bone well, fusing it all together.

Over the past decade Dunlop and Prof Richard Oreffo, at Southampton University, have developed a translational research programme to drive bone formation using patient skeletal stem cells in orthopaedics.

The graft used in the operation is made up of a bone scaffold that allows blood to flow through it. Stem cells from the bone marrow will attach to the material and grow new bone, which will support the 3D printed hip implant.

In a statement, Prof Oreffo said: The 3D printing of the implant in titanium, from CT scans of the patient and stem cell graft is cutting edge and offers the possibility of improved outcomes for patients.

Fractures and bone loss due to trauma or disease are a significant clinical and socioeconomic problem. Growing bone at the point of injury alongside a hip implant that has been designed to the exact fit of the patient is exciting and offers real opportunities for improved recovery and quality of life.

Original post:
Patient receives 3D printed titanium hip

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise SALT LAKE CITY In the body, a skin cell will always be skin, and a heart cell will always be heart. But in the first hours of life, cells in the nascent embryo become totipotent: they have the incredible flexibility to mature into skin, heart, gut, or any type of cell.

It was long assumed that the joining of egg and sperm launched a dramatic change in how and which genes were expressed. Instead, new research shows that totipotency is a step-wise process, manifesting as early as in precursors to sperm, called adult germline stem cells (AGSCs), which reside in the testes.

The study was co-led by Bradley Cairns, Ph.D., University of Utah professor of oncological sciences, and Huntsman Cancer Institute investigator, and Ernesto Guccione, Ph.D., of the Agency for Science Technology and Research in Singapore. They worked closely with first author and Huntsman Cancer Institute postdoctoral fellow, Saher Sue Hammond, Ph.D. The research was published online in the journal Cell Stem Cell.

Typically, sperm precursors live a mundane life. They divide, making more cells like themselves, until they receive the signal instructing them to mature into sperm.

There is evidence, however, that these cells have the potential to do more. Under the unusual conditions that promote the cells to form dense cancerous masses called testicular teratomas, the young sperm transform into precursors of skin, muscle, and gut.

This realization prompted the investigators to examine the gene program within sperm precursors. They wondered, would it be like that of a cell that is destined to become a single cell type, or like that of a cell with the potential to become anything?

The answer, they found, is that the sperm precursors are somewhere in between. The most telling evidence is the status of a quartet of genes: Lefty, Sox2, Nanog, and Prdm14. When activated, the genes can trigger a cascade of events that give cells stem cell properties. In cells limited to becoming one cell type, the genes are silent.

Yet in sperm precursors, the genes bear a code of chemical tags, called methylation groups, indicating that the four genes are silenced, but poised to become active. In other words, embedded within these cells, is the potential to become totipotent.

Continue reading here:
The Young Sperm, Poised for Greatness

Recommendation and review posted by Bethany Smith

On The Offensive Against GMOs with Jeffrey Smith
Genetic engineering of foods is one of the most controversial subjects of the last two decades. Since humans first domesticated crops and animals, people have bred different breeds and species...

By: NextNewsNetwork

Visit link:
On The Offensive Against GMOs with Jeffrey Smith - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

19-May-2014

Contact: Kathryn Ruehle kruehle@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 19, 2014Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD). The results of these first controlled trials of duloxetine in pediatric patients with MDD are published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The articles are available free on the Journal of Child and Adolescent Psychopharmacology

Graham Emslie, MD and coauthors evaluated the efficacy and safety of a fixed dose of duloxetineeither 60 mg or 30 mg once a dayversus 20 mg daily of fluoxetine or placebo in children ages 7-11 years and adolescents ages 12-17 years. In the article "A Double-Blind Efficacy and Safety Study of Duloxetine Fixed Doses in Children and Adolescents with Major Depressive Disorder" they compare the treatments based on worsening of suicidal ideation, emergence of suicidal behavior, and adverse effects including abnormal findings on an electrocardiogram and laboratory tests.

Sarah Atkinson, MD and colleagues compared a flexible dosing regimen of duloxetine (60-120 mg daily) to fluoxetine (20-40 mg daily) or placebo and reported measures from a depression rating scale and a suicide severity rating scale, as well as treatment-related adverse events, in the article "A Double-Blind Efficacy and Safety Study of Duloxetine Flexible Dosing in Children and Adolescents with Major Depressive Disorder".

Neither study found a significant difference in response between the two drugs and placebo. The authors suggest that this may be due to the complexity of these novel studies and offer observations that may direct the design of future investigations.

"Drs. Emslie and Atkinson and their colleagues took a fascinating approach towards testing the efficacy of a novel SNRI in the pediatric population," said Harold S. Koplewicz, MD, Editor-in-Chief of Journal of Child and Adolescent Psychopharmacology, and President, Child Mind Institute, New York, NY. "Researchers are of course excited by positive results, but in this case the curious lack of response tells us volumes about how to better design complex studiesstudies that may soon give us uncommon insight into our pharmacologic interventions."

###

About the Journal

Read more:
Is Duloxetine more or less effective than Fluoxetine in children and teens with MDD?

Recommendation and review posted by Bethany Smith

Researchers at the Weill Medical College in Qatar (WCMC-Q) have published the first genetic map of the date palm, according to a report. The genetic map shows the order in which the date palms chromosomes are placed and also which chromosome is responsible for reproduction. In theory, the information could one day allow growers to manipulate the development of seeds, creating more female fruit-bearing plants than male plants that do not produce dates, an important food source for much of the Middle East, the report said. Scientists from Saudi Arabia and China completed mapping the genome of the date-palm tree late last year. Scientists from Riyadhs King Abdulaziz City for Science and Technology (KACST) and Chinas Shenzhen-based BGI had been working on the project since 2008. The map has been produced by the genomics group under the direction of Joel Malek, assistant professor of Genetic Medicine at WCMC-Q, in collaboration with Karsten Suhre, professor of physiology and biophysics at WCMC-Q, and with the help of colleagues at the Ministry of Environments Biotechnology Center and the Department of Agricultural Affairs. The program, entitled Establishing World Leadership in Date Palm Research in Qatar, was funded by the National Priorities Research Program (NPRP) at the Qatar National Research Fund (QNRF), which provided $4.5 million to the research. Malek and his team produced a draft version of the date palm genome three years ago. It was this that paved the way for the more accurate map. To create the map, Malek and Suhre worked with the Ministry of the Environments Biotechnology Center and their Department of Agricultural Affairs. The ministry provided the researchers with 150 seeds from a single female tree, which were then propagated by Ameena Al-Malki at the Biotechnology Center. Leaves and DNA were taken from the seedlings once they were large enough for testing. A new process called genotyping-by-sequencing was then applied which sequenced portions of the genomes of all 150 seedlings. It allowed the researchers to look at the parent tree and ascertain how the DNA was passed to the offspring. Khaled Machaca, associate dean of research at WCMC-Q, said the research demonstrates the value of funding novel, regionally relevant, collaborative research between different organizations. The NPRP exceptional proposal (NPRP-EP) funding the date palm research was the first NPRP-EP awarded by QNRF, he said. It funds regionally relevant research that has a high likelihood of contributing toward Qatars knowledge-based economy vision. This funding is beginning to bear fruits by generating the first chromosome map for date palm through collaborative efforts of multiple institutions in Qatar.

See the original post:
Worlds first date palm genetic map published

Recommendation and review posted by Bethany Smith

Restoration of Function After Spinal Cord Injury
Grand Rounds in Neuroscience ant the University of Louisville. Presenter: Graham Creasey, MD, Paralyzed Veterans of America Professor of Spinal Cord Injury M...

By: UofL Neurosurgery

Read more here:
Restoration of Function After Spinal Cord Injury - Video

Recommendation and review posted by sam

The Site Of Insult: Spinal Cord Injury, "Push Girls" The Ground Zero Of Female Pleasure"
Neuroscience Grand Rounds 2/13/14 - "The Site Of Insult: Spinal Cord Injury, "Push Girls" The Ground Zero Of Female Pleasure" Presenter: Krista Kane, Direc...

By: UofL Neurosurgery

Go here to see the original:
The Site Of Insult: Spinal Cord Injury, "Push Girls" & The Ground Zero Of Female Pleasure" - Video

Recommendation and review posted by sam

Fighting Something Big- Monica
Monica experienced a spinal cord injury while skiing. Since then, she has become an olympic athlete for both hand cycling and cross-country skiing.

By: Calvin McNelly

Original post:
Fighting Something Big- Monica - Video

Recommendation and review posted by sam